CRISPR genome editing: A general view

Ram Mohan Ram Kumar*

Published: 23 June, 2017 | Volume 1 - Issue 1 | Pages: 001-002

CRISPR technology has presented a path forward for genomic engineering and gene modification. The framework for the use of CRISPR technology to manipulate the human genome is of great interest and the form of its development and application has excited the researchers and biotech communities as the number of publications citing CRISPR gene targeting system has rose predominantly as indexed in PubMed. From a technical standpoint of view, most of us think that this would be relatively straightforward process, but technical feasibility is never the only consideration in doing experiments. Much of the discussion about CRISPR engineering has revolved mostly around its ability for treating disease or editing the genes of human embryos. In the real sense, what the biologists desire about CRISPR is its specificity: the ability to target and determine particular DNA sequences in the genome circuit.

Read Full Article HTML DOI: 10.29328/journal.jgmgt.1001001 Cite this Article Read Full Article PDF


  1. Barrangou R. RNA events. Cas9 targeting and the CRISPR revolution. Science. 2014; 344: 707-708. Ref.: https://goo.gl/PDBhc1
  2. Xie F, Ye L, Chang JC, Beyer AI, Wang J, et al. Seamless gene correction of β-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac. Genome Res. 2014; 24: 1526-1533. Ref.: https://goo.gl/4JWJM4
  3. Ebina H, Misawa N, Kanemura Y, Koyanagi Y. Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus. Sci Rep. 2013; 3: 2510. Ref.: https://goo.gl/BFzgBn
  4. Schwank G, Koo BK, Sasselli V, Dekkers JF, Heo I, et al. Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell. 2013; 13: 653-658. Ref.: https://goo.gl/82stVs
  5. Li HL, Fujimoto N, Sasakawa N, Shirai S, Ohkame T, et al. Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9. Stem Cell Reports. 2015; 4:143-54. Ref.: https://goo.gl/zHQsA6
  6. Long C, Amoasii L, Mireault AA, McAnally JR, Li H, et al. Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science. 2016; 351: 400-403. Ref.: https://goo.gl/e9FdEx
  7. Nelson CE, Hakim CH, Ousterout DG, Thakore PI, Moreb EA, et al. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science. 2015; 351: 403-407. Ref.: https://goo.gl/2boVPL
  8. Tabebordbar M, Zhu K, Cheng JK, Chew WL, Widrick JJ, et al. In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science. 2015; 351: 407-411. Ref.: https://goo.gl/pm4wZ5
  9. Iyombe-Engembe JP, Ouellet DL, Barbeau X, Rousseau J, Chapdelaine P, et al. Efficient Restoration of the Dystrophin Gene Reading Frame and Protein Structure in DMD Myoblasts Using the CinDel Method. Mol Ther Nucleic Acids. 2016; Ref.: https://goo.gl/mvNd4b


Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?